share_log

Clover Health | 10-Q: Q2 2024 Earnings Report

Clover Health | 10-Q: Q2 2024 Earnings Report

Clover Health | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/08 20:09

Moomoo AI 已提取核心訊息

Clover Health reported strong financial results for Q2 2024, with total revenue increasing 11.3% year-over-year to $356.3 million, driven by an 11.3% rise in premiums earned to $349.9 million. The company achieved net income of $7.4 million, a significant improvement from a $28.8 million loss in Q2 2023, while maintaining a medical care ratio of 74.5%.Operating expenses remained stable at $349.1 million as reduced salaries and benefits costs offset higher medical claims. The company's Insurance segment served 80,261 Medicare Advantage members across five states, with gross profit increasing to $104.5 million. Cash and investments strengthened to $482.8 million at quarter-end, up from $417.3 million at year-end 2023.During the quarter, Clover Health launched Counterpart Health, a new SaaS solution to extend its AI-powered care management platform to external Medicare Advantage payors and providers. The company also received an upgraded CMS Star rating of 3.5 for its PPO Medicare Advantage plans for the 2025 payment year, reflecting improved performance metrics.
Clover Health reported strong financial results for Q2 2024, with total revenue increasing 11.3% year-over-year to $356.3 million, driven by an 11.3% rise in premiums earned to $349.9 million. The company achieved net income of $7.4 million, a significant improvement from a $28.8 million loss in Q2 2023, while maintaining a medical care ratio of 74.5%.Operating expenses remained stable at $349.1 million as reduced salaries and benefits costs offset higher medical claims. The company's Insurance segment served 80,261 Medicare Advantage members across five states, with gross profit increasing to $104.5 million. Cash and investments strengthened to $482.8 million at quarter-end, up from $417.3 million at year-end 2023.During the quarter, Clover Health launched Counterpart Health, a new SaaS solution to extend its AI-powered care management platform to external Medicare Advantage payors and providers. The company also received an upgraded CMS Star rating of 3.5 for its PPO Medicare Advantage plans for the 2025 payment year, reflecting improved performance metrics.
Clover Health在2024年第二季度報告了強勁的財務業績，總營業收入同比增長11.3%，達到了35630萬元，這主要得益於保費收入的11.3%增長，達到了34990萬元。公司實現凈利潤740萬元，較2023年第二季度的2880萬元虧損有了顯著改善，同時維持了74.5%的醫療保健比例。營業費用保持穩定，爲34910萬元，工資和福利成本的減少抵消了醫療索賠的增加。公司在保險領域服務於80261名在五個州的醫療補助優先成員，毛利潤增加至10450萬元。季度末現金和投資增強至48280萬元，較2023年年末的41730萬元有所增長。在本季度，Clover Health推出了Counterpart Health，這是一個新的Saas-雲計算解決方案，旨在將其人工智能驅動的護理管理平台擴展到外部的醫療補助優先支付者和提供者。公司還獲得了2025年支付年度PPO醫療補助優先計劃的CMS科創板評級3.5的提升，反映了績效指標的改善。
Clover Health在2024年第二季度報告了強勁的財務業績，總營業收入同比增長11.3%，達到了35630萬元，這主要得益於保費收入的11.3%增長，達到了34990萬元。公司實現凈利潤740萬元，較2023年第二季度的2880萬元虧損有了顯著改善，同時維持了74.5%的醫療保健比例。營業費用保持穩定，爲34910萬元，工資和福利成本的減少抵消了醫療索賠的增加。公司在保險領域服務於80261名在五個州的醫療補助優先成員，毛利潤增加至10450萬元。季度末現金和投資增強至48280萬元，較2023年年末的41730萬元有所增長。在本季度，Clover Health推出了Counterpart Health，這是一個新的Saas-雲計算解決方案，旨在將其人工智能驅動的護理管理平台擴展到外部的醫療補助優先支付者和提供者。公司還獲得了2025年支付年度PPO醫療補助優先計劃的CMS科創板評級3.5的提升，反映了績效指標的改善。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Oscar Health
    OSCR
    -- 13.460
    Molina Healthcare
    MOH
    -- 272.280
    哈門那
    HUM
    -- 253.830
    康西哥
    CNC
    -- 56.860
    NeueHealth
    NEUE
    -- 7.330
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！